Abstract 4099
Background
The aim of this study was to analyze the safety and effectiveness of different preoperative preparation time in the neoadjuvant chemotherapy (SOX) regimen in patients with advanced gastric cancer.
Methods
From June 1 2010 to June 1 2017, 120 patients aged from 25 to 80 with clinical stage IIA-IIIC gastric cancer received neoadjuvant chemotherapy with S-1 and oxaliplatin and radical gastrectomy in Chinese PLA General Hospital. They were eligible for inclusion and they were randomly assigned to either the 3-weeks group, which received radical gastrectomy 3 weeks after neoadjuvant chemotherapy (n = 60), or the 5-weeks group, which received radical gastrectomy 5 weeks after neoadjuvant chemotherapy (n = 60). We compared short-term surgical outcomes between the two groups.
Results
There were no significant differences between the two groups regarding the clinical pathological characteristics. However, the 5-weeks group had less intraoperative blood loss (229 ml vs 240 ml, P = 0.031) and less Clavien-Dindo grade II to IV complications (P = 0.006) than the 3-weeks group. Baseline clinicopathologic characteristics, and short-term outcomes of the patients treated in the two groups were similar.
Conclusions
Patients with advanced gastric cancer undergoing advanced neoadjuvant chemotherapy after neoadjuvant chemotherapy require a certain amount of time to adjust and prepare for gastrectomy. Considering the general condition of the patients, the preoperative interval can be shortened and the efficacy can be improved.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Wangxinxin.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1619 - Meta-analysis of KRAS Mutation as prognostic factor in patients (pts.) with resection of colorectal (CRC) liver metastases: Tumor burden and Sideness analysis.
Presenter: Maria Romina Luca
Session: Poster Display session 2
Resources:
Abstract
2104 - Clinical implications of regorafenib-induced hypothyroidism in metastatic colorectal cancer refractory to standard therapies: A prospective evaluation
Presenter: Jwa Hoon Kim
Session: Poster Display session 2
Resources:
Abstract
2143 - Clinical impact of BRAF V600E mutations in patients (pts) with resectable solitary colorectal liver metastases (CRLM)
Presenter: Shin Kobayashi
Session: Poster Display session 2
Resources:
Abstract
3136 - Trifluridine/tipiracil in metastatic colorectal cancer: an updated multicentre real-world analysis on efficacy, safety and predictive factors.
Presenter: Chara Stavraka
Session: Poster Display session 2
Resources:
Abstract
4234 - Correlation between p53 expression and clinical outcome in RAS/BRAF wild type metastatic colorectal cancer patients receiving later-line irinotecan-cetuximab
Presenter: Eleonora Lai
Session: Poster Display session 2
Resources:
Abstract
4287 - Safety and effectiveness of aflibercept + FOLFIRI for the treatment of patients with metastatic colorectal cancer (mCRC): OZONE secondary analyses
Presenter: Ian Chau
Session: Poster Display session 2
Resources:
Abstract
1820 - A Phase Ib study of the safety and efficacy of atezolizumab (atezo) + bevacizumab (bev) + cobimetinib (cobi) in patients (pts) with metastatic colorectal cancer (mCRC)
Presenter: Johanna Bendell
Session: Poster Display session 2
Resources:
Abstract
5644 - Development and validation of a metastasis-associated immune prognostic model for concurrent metastatic colorectal cancer
Presenter: Zhiwen Luo
Session: Poster Display session 2
Resources:
Abstract
5697 - Prognostic role of blood cell count-based immuno-inflammatory parameters in the Valentino trial
Presenter: Giovanni Fuca
Session: Poster Display session 2
Resources:
Abstract
4704 - Evaluation of safety, immunogenicity and preliminary efficacy of PolyPEPI1018 vaccine in subjects with metastatic colorectal cancer (mCRC) with a predictive biomarker
Presenter: Joleen Hubbard
Session: Poster Display session 2
Resources:
Abstract